%0 Journal Article
%T 塞来昔布在消化道肿瘤中的治疗研究进展<br>Progress in the Treatment of Celecoxib in Digestive Tract Tumors
%A 姜婷婷
%A 李瑜英
%J Advances in Clinical Medicine
%P 10747-10752
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1371501
%X 炎症细胞参与肿瘤过程，促进肿瘤细胞生长、侵袭及转移。癌症组织中不仅存在环氧合酶-2的过表达且与肿瘤的不良预后有关。塞来昔布是一种COX-2选择性抑制剂，可通过多种分子机制干预肿瘤发展并减少耐药性的形成。作用靶点广，可抑制肿瘤细胞增殖、浸润、转移及肿瘤新生血管生成、诱导肿瘤细胞分化、促进凋亡、调节肿瘤免疫、逆转肿瘤细胞多药耐药，从而发挥良好的临床抗肿瘤效果。本文试图总结阐明塞来昔布在消化道肿瘤治疗和预防中的最新研究。<br />
Inflammatory cells are involved in the tumor process and promote the tumor cell growth, invasion, and metastasis. Overexpression of cyclooxygenase-2 is not only present in cancer tissues but also associated with poor prognosis of tumors. Celecoxib is a selective inhibitor of COX-2 that can in tu-mor development and reduces resistance formation through a variety of molecular mechanisms. Wide targets can inhibit tumor cell proliferation, infiltration, metastasis and tumor neoangiogene-sis, induce tumor cell differentiation, promote apoptosis, regulate tumor immunity, reverse multi-drug resistance of tumor cells, so as to play a good clinical anti-tumor effect. This paper attempts to summarize the latest studies elucidating celecoxib in the treatment and prevention of digestive tract tumors.
%K 塞来昔布，食管癌，胃癌，结直肠癌，治疗研究进展<br>Celecoxib
%K Esophageal Cancer
%K Gastric Cancer
%K Colorectal Cancer
%K Advances in Treatment Research
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=68403